ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Chirality-Converted Bacteriolytic Dodecapeptide Regulates Vibrio-Induced Polymicrobial Infection and Ameliorates Invasion-Associated Gut Microbiota Disequilibrium.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Chirality-Converted Bacteriolytic Dodecapeptide Regulates Vibrio-Induced Polymicrobial Infection and Ameliorates Invasion-Associated Gut Microbiota Disequilibrium.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The polymicrobial infections caused by Vibrio species, especially multidrug-resistant isolates, are posing increasing threats to the health of coastal residents. Herein, a novel dodecapeptide, denoted as D-zp37, was designed and synthesized, aiming to combat these notorious pathogens. Experimental results proved that the simple chirality conversion of the parent peptide, zp37, could significantly boost the antibacterial activity and proteolytic stability. To a specific cephalosporin-resistant Vibrio alginolyticus, the minimal inhibitory concentration value of D-zp37 was as low as 0.5 µm. Beyond the strong bacteriolytic effect against planktonic Vibrio alginolyticus, Vibrio parahaemolyticus and Vibrio vulnificus strains, D-zp37 was found to restrain the biofilm establishment of Vibrio mixtures via inhibiting the efflux of intracellular polysaccharides. Mechanistic studies hinted that D-zp37 impeded the electron transport chain, impaired the membrane stress response by downregulating the phage shock protein family, and blocked amino acid biosynthesis in Vibrio cells. Furthermore, three different infection models (shrimp, Galleria mellonella larvae and immunosuppressed mice) collaboratively confirmed the anti-Vibrio efficacy of D-zp37 in vivo. In addition, the intragastric administration of D-zp37 was found to be beneficial in restoring the imbalanced gut microbiota induced by the polymicrobial Vibrio invasion. In summary, this work investigated the antibacterial mechanisms and in vivo efficacy of a novel peptide lead compound, proposing a new therapeutic against Vibrio infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.